OraSure Technologies (NASDAQ:OSUR) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “

Several other equities analysts have also recently issued reports on OSUR. ValuEngine upgraded shares of OraSure Technologies from a sell rating to a hold rating in a research report on Wednesday, October 2nd. BidaskClub upgraded shares of OraSure Technologies from a sell rating to a hold rating in a research report on Saturday, November 30th. Finally, Canaccord Genuity restated a hold rating and issued a $8.00 price target on shares of OraSure Technologies in a research report on Monday, November 11th.

OSUR stock traded up $0.06 during trading on Wednesday, reaching $7.91. 12,843 shares of the company were exchanged, compared to its average volume of 473,483. The company has a 50-day moving average of $8.18 and a two-hundred day moving average of $8.05. The company has a market capitalization of $487.02 million, a price-to-earnings ratio of 15.88, a P/E/G ratio of 4.51 and a beta of 1.19. OraSure Technologies has a twelve month low of $6.35 and a twelve month high of $13.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.72 and a quick ratio of 6.85.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.18. The business had revenue of $35.99 million during the quarter, compared to analysts’ expectations of $38.62 million. OraSure Technologies had a net margin of 15.80% and a return on equity of 5.93%. The firm’s quarterly revenue was down 21.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.13 EPS. On average, analysts forecast that OraSure Technologies will post 0.14 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in OSUR. Acadian Asset Management LLC acquired a new position in OraSure Technologies in the 2nd quarter valued at approximately $25,000. BSW Wealth Partners bought a new stake in shares of OraSure Technologies in the 2nd quarter valued at $29,000. Panagora Asset Management Inc. boosted its stake in shares of OraSure Technologies by 34.3% in the 2nd quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock valued at $91,000 after purchasing an additional 2,514 shares during the last quarter. Quantamental Technologies LLC boosted its stake in shares of OraSure Technologies by 107.0% in the 2nd quarter. Quantamental Technologies LLC now owns 10,311 shares of the medical instruments supplier’s stock valued at $96,000 after purchasing an additional 5,330 shares during the last quarter. Finally, Pacer Advisors Inc. bought a new stake in shares of OraSure Technologies in the 2nd quarter valued at $104,000. Hedge funds and other institutional investors own 95.66% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Article: What is the definition of a trade war?

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.